Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5537737 | Vaccine | 2016 | 10 Pages |
Abstract
A safer and more effective vaccine than the unlicensed Francisella tularensis Live Vaccine Strain (LVS) is needed to protect against the biowarfare agent F. tularensis. Previously, we developed an LVS ÎcapB mutant that is significantly safer than LVS and provides potent protective immunity against F. tularensis respiratory challenge when administered intranasally but limited protection when administered intradermally unless as part of a prime-boost vaccination strategy. To improve the immunogenicity and efficacy of LVS ÎcapB, we developed recombinant LVS ÎcapB (rLVS ÎcapB) strains overexpressing various F. tularensis Francisella Pathogenicity Island (FPI) proteins - IglA, IglB and IglC, and a fusion protein (IglABC) comprising immunodominant epitopes of IglA, IglB, and IglC downstream of different Francisella promoters, including the bacterioferritin (bfr) promoter. We show that rLVS ÎcapB/bfr-iglA, iglB, iglC, and iglABC express more IglA, IglB, IglC or IglABC than parental LVS ÎcapB in broth and in human macrophages, and stably express FPI proteins in macrophages and mice absent antibiotic selection. In response to IglC and heat-inactivated LVS, spleen cells from mice immunized intradermally with rLVS ÎcapB/bfr-iglC or bfr-iglABC secrete greater amounts of interferon-gamma and/or interleukin-17 than those from mice immunized with LVS ÎcapB, comparable to those from LVS-immunized mice. Mice immunized with rLVS ÎcapB/bfr-iglA, iglB, iglC or iglABC produce serum antibodies at levels similar to LVS-immunized mice. Mice immunized intradermally with rLVS ÎcapB/bfr-iglABC and challenged intranasally with virulent F. tularensis Schu S4 survive longer than sham- and LVS ÎcapB-immunized mice. Mice immunized intranasally with rLVS ÎcapB/bfr-iglABC - but not with LVS - just before or after respiratory challenge with F. tularensis Schu S4 are partially protected; protection is correlated with induction of a strong innate immune response. Thus, rLVS ÎcapB/bfr-iglABC shows improved immunogenicity and protective efficacy compared with parental LVS ÎcapB and, in contrast to LVS, has partial efficacy as immediate pre- and post-exposure prophylaxis.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Qingmei Jia, Richard Bowen, Bai-Yu Lee, Barbara Jane Dillon, SaÅ¡a MasleÅ¡a-GaliÄ, Marcus A. Horwitz,